Alcobra Ltd. (NASDAQ:ADHD) – Equities researchers at Jefferies Group raised their FY2017 earnings per share (EPS) estimates for Alcobra in a research note issued to investors on Thursday. Jefferies Group analyst B. Amin now forecasts that the brokerage will earn ($1.00) per share for the year, up from their previous forecast of ($1.07). Jefferies Group has a “Buy” rating and a $6.00 price target on the stock. Jefferies Group also issued estimates for Alcobra’s FY2018 earnings at ($0.97) EPS, FY2019 earnings at ($1.09) EPS and FY2020 earnings at ($1.12) EPS.
A number of other equities analysts also recently weighed in on ADHD. Roth Capital set a $8.00 target price on shares of Alcobra and gave the stock a “buy” rating in a report on Saturday. Cantor Fitzgerald assumed coverage on shares of Alcobra in a report on Tuesday, June 7th. They set a “buy” rating and a $16.00 target price on the stock. Piper Jaffray Cos. downgraded shares of Alcobra from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $10.00 to $3.00 in a report on Thursday, September 29th. Zacks Investment Research upgraded shares of Alcobra from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Alcobra in a report on Thursday, September 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.47.
Shares of Alcobra (NASDAQ:ADHD) traded up 1.15% during trading on Monday, reaching $2.63. 169,860 shares of the company traded hands. The company has a 50-day moving average of $4.62 and a 200-day moving average of $4.50. The stock’s market capitalization is $72.49 million. Alcobra has a 12 month low of $1.95 and a 12 month high of $8.78.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01.
Institutional investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp increased its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Jefferies Group LLC acquired a new position in Alcobra during the second quarter valued at approximately $533,000. Palo Alto Investors LLC increased its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the period. BlackRock Fund Advisors increased its position in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock valued at $1,344,000 after buying an additional 36,218 shares during the period. Finally, VHCP Management LLC increased its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.
Alcobra Company Profile
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.